Techsomed

Company Overview

Snapshot

Founded in August 2012 by Yossi Abu, Techsomed operates with 11–50 employees. In January 2024, Techsomed's BioTrace solution achieved De Novo clearance from the FDA, marking it as the first ultrasound-based software for tissue response prediction in liver tumor ablation.

Business overview

Techsomed is a medical software company that leverages generative AI to enhance ablation therapy, a minimally invasive technique used for treating tumors, heart arrhythmias, and chronic pain. Its flagship product, the BioTraceIO360 software suite, focuses on liver tumor ablation procedures, utilizing standard medical imaging modalities like Ultrasound, CT, and MRI to provide physicians with tissue damage prediction, advanced patient-specific treatment planning, and interactive ablation procedure analysis. The company serves the Health Tech & Life Sciences sector, specifically within Digital Healthcare and Medical Decision Support, operating globally with subsidiaries in Germany and Japan to support R&D and commercialization efforts in Asian markets.

Strategic signal

Techsomed is demonstrating strong momentum in regulatory approvals and market expansion. In September 2025, the company received FDA 510(k) clearance to expand its BioTraceIO360 platform to kidney ablation, signifying a strategic move towards a unified multi-organ image-guided therapy platform. This expansion, following previous FDA clearances for liver tumor ablation, indicates a clear trajectory towards broader clinical applications and market penetration, positioning Techsomed as a leader in AI-driven precision for image-guided care.

Company Intelligence Q&A

What significant regulatory clearance did Techsomed receive in January 2024?

In January 2024, Techsomed's BioTrace solution achieved De Novo clearance from the FDA, making it the first ultrasound-based software for tissue response prediction in liver tumor ablation.

What was the key development for Techsomed in September 2025?

In September 2025, Techsomed received U.S. FDA 510(k) clearance, expanding the indications for its BioTraceIO360 platform to include kidney ablation, advancing its multi-organ image-guided therapy platform.

Which investors participated in Techsomed's Series B financing round in March 2021?

In March 2021, Techsomed raised Series B financing led by Axil Capital, with participation from.

What strategic collaboration did Techsomed announce in October 2025?

In October 2025, Techsomed announced a collaboration with Medtronic focused on image-guided ablation therapy.

What was the purpose of Techsomed's new German subsidiary opened in December 2022?

In December 2022, Techsomed opened a new German subsidiary as part of a strategic collaboration with the Fraunhofer MEVIS research institute, aimed at accelerating an end-to-end solution for image-guided tumor ablation therapy.